A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma

Masafumi Yamashita, Hiroshi Wada, Hidetoshi Eguchi, Hisataka Ogawa, Daisaku Yamada, Takehiro Noda, Tadafumi Asaoka, Koichi Kawamoto, Kunihito Gotoh, Koji Umeshita, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Cancer stem cells (CSCs) were reported to be involved in resistance to chemo/radiation therapy. We previously reported that CD13 was both a marker of CSCs and a candidate therapeutic target in HCC. In the present study, we explored the antitumor effect of a combined therapy, where ubenimex, a CD13 inhibitor, was combined with conventional anticancer drugs, fluorouracil (5-FU), cisplatin (CDDP), doxorubicin (DXR) and sorafenib (SOR), and we elucidated the mechanism of these combination therapies. We evaluated changes in the expression of CD13 before and after treatment with anticancer drugs and with or without ubenimex in the human HCC cell lines HuH7 and PLC/PRF/5. The interactions between the anticancer drugs and ubenimex were determined with isobologram analyses. We analyzed cell cycle, apoptosis, and intracellular reactive oxygen species (ROS) levels to explore the mechanisms of the combination therapies. In both cell lines, the expression of CD13 increased after a 72-h exposure to each anticancer drug alone (p<0.05), and the expression of CD13 decreased with ubenimex administration (p<0.05). Isobologram analyses indicated that ubenimex had synergistic effects with 5-FU, CDDP and DXR, and an additive effect with SOR. Cell cycle analyses showed that ubenimex decreased the proportion of cells in G0/G1. Ubenimex enhanced the effects of 5-FU, CDDP and DXR by increasing apoptosis and intracellular ROS levels. In combination therapies, ubenimex synergistically enhanced the antitumor effects of 5-FU, CDDP and DXR on cell cycle regulation and apoptosis induction in HCC cell lines. The effects of ubenimex were due to increased intracellular ROS levels.

Original languageEnglish
Pages (from-to)89-98
Number of pages10
JournalInternational journal of oncology
Volume49
Issue number1
DOIs
Publication statusPublished - Jul 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Yamashita, M., Wada, H., Eguchi, H., Ogawa, H., Yamada, D., Noda, T., Asaoka, T., Kawamoto, K., Gotoh, K., Umeshita, K., Doki, Y., & Mori, M. (2016). A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma. International journal of oncology, 49(1), 89-98. https://doi.org/10.3892/ijo.2016.3496